Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Free Report) Director Adrian Senderowicz sold 27,000 shares of the business’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $7.20, for a total transaction of $194,400.00. Following the completion of the transaction, the director owned 27,000 shares in the company, valued at approximately $194,400. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Puma Biotechnology Stock Up 1.4%
PBYI stock opened at $7.17 on Wednesday. The firm has a market cap of $364.95 million, a price-to-earnings ratio of 14.94 and a beta of 1.21. Puma Biotechnology, Inc. has a 12-month low of $3.03 and a 12-month high of $7.90. The company’s fifty day simple moving average is $7.24 and its 200 day simple moving average is $6.58.
Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.09. Puma Biotechnology had a net margin of 10.69% and a return on equity of 20.30%. The firm had revenue of $44.81 million during the quarter, compared to the consensus estimate of $42.00 million. Research analysts expect that Puma Biotechnology, Inc. will post 0.28 earnings per share for the current year.
Institutional Investors Weigh In On Puma Biotechnology
Analysts Set New Price Targets
Several equities research analysts have weighed in on the stock. Wall Street Zen downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 16th. Weiss Ratings downgraded shares of Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold”.
View Our Latest Research Report on Puma Biotechnology
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.
The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.
Featured Stories
- Five stocks we like better than Puma Biotechnology
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
